SystImmune Announces FDA Clearance for BL-M17D1 IND Application
08 Nov 2024 //
PR NEWSWIRE
SystImmune Announces FDA Clearance Of IND For BL-M11D1
14 Oct 2024 //
PR NEWSWIRE
SystImmune To Present BL-B01D1 Cancer Data At ESMO 2024
09 Sep 2024 //
PR NEWSWIRE
Systimmune Appoints Cmo: Dr. Jonathan Cheng Joins Leadership
23 May 2024 //
PR NEWSWIRE
SystImmune Appoints Dr. Jie D`Elia As CEO
22 Apr 2024 //
PR NEWSWIRE
SystImmune Names New CEO
22 Apr 2024 //
PR NEWSWIRE
SystImmune Announces Presentation of Breast Cancer Clinical Trial Results
05 Dec 2023 //
PR NEWSWIRE
SystImmune Announces First Patient Dosed in U.S. Phase 1 Trial of BL-B01D1
12 Oct 2023 //
PR NEWSWIRE